â?? Role of Markatbija churn on Respiratory Rate in Tamak Shvasa with special reference to Bronchial Asthmaâ??

Phase 2

Conditions: Health Condition 1: J454- Moderate persistent asthmaHealth Condition 2: J454- Moderate persistent asthma

Registration Number: CTRI/2022/03/040712

Lead Sponsor: Government ayurved college and hospital

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

1. Patient of Tamak Shvasa presenting the clinical features highlighted in classical literature will be randomly irrespective of sex , caste , religion and socio economical status.

2. Patient of Tamak Shvasa ageing in between 16 to 60 years will be considered.

3. Patient from mild to moderate exacerbation of bronchial asthma.

4. Positive test of reversibility-

a) symptomatic patients- An improvement of 60 L / min or > 20 % in PEFR 10 min after inhalation of bronchodilator ( salbutamol ) .

b) Asymptomatic patient 60 L / min or > 20 % fall in PEFR by provocation with physical exercise ( brisk walking for 5-10 min ) followed by reversal upon in Inhalation of bronchodilator ( salbutamol) when assessed after 10 min .

6. Heemoglobin >10 gm%.

7. Patient willing and able to participate for 4 weeks.

8. Patient showing symptoms, signs and medical history of bronchial asthma will be included.

Exclusion Criteria

Patient with active lung disease, patient with lung disease other than bronchial asthma, patient who had major surgeries within 2 weeks prior to screening visited , patient with evidence of malignancy, patient with severe asthma exacerbation, pregnant or lactating , patient with poorly controlled hypertension ( >160/100 mmhg) , patient with uncontrolled diabetes mellitus ( blood sugar fasting >130 mg /dl and post meal 250 mg /dl )

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.To evaluate the efficacy of markatbija churn in management of Tamak Shvasa specifically on respiratory rate , peak exploratory flow rate, sustained maximum inspiration and MRC dyspnoea scale. <br/ ><br>2. To study the effect of Deriphylline retard in the management of Tamak Shvasa specifically on respiratory rate , peak expiratory flow rate, sustained maximal inspiration and MRC dyspnoea scale. <br/ ><br>3. To compare the effect of markatbija churn with tablet Deriphylline retard with respect to respiratory rate , peak expiratory flow rate , sustained maximal inspiration and MRC dyspnoea scale.Timepoint: 18 months

Secondary Outcome Measures